Canada Pension Plan Investment Board Raises Stock Position in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX)

Canada Pension Plan Investment Board boosted its position in shares of Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) by 2.3% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 365,300 shares of the company’s stock after acquiring an additional 8,300 shares during the period. Canada Pension Plan Investment Board owned 0.12% of Amneal Pharmaceuticals worth $2,893,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors also recently bought and sold shares of the company. Jump Financial LLC purchased a new stake in shares of Amneal Pharmaceuticals during the 4th quarter valued at $1,314,000. XTX Topco Ltd increased its position in Amneal Pharmaceuticals by 75.8% during the 4th quarter. XTX Topco Ltd now owns 39,055 shares of the company’s stock valued at $309,000 after buying an additional 16,845 shares in the last quarter. Mariner LLC raised its stake in Amneal Pharmaceuticals by 3,749.1% in the fourth quarter. Mariner LLC now owns 424,291 shares of the company’s stock valued at $3,360,000 after buying an additional 413,268 shares during the last quarter. Barclays PLC boosted its holdings in Amneal Pharmaceuticals by 18.9% in the fourth quarter. Barclays PLC now owns 352,494 shares of the company’s stock worth $2,792,000 after acquiring an additional 56,110 shares in the last quarter. Finally, Raymond James Financial Inc. purchased a new stake in shares of Amneal Pharmaceuticals during the fourth quarter worth about $2,946,000. 31.82% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of analysts recently commented on the stock. Barclays lifted their target price on shares of Amneal Pharmaceuticals from $10.00 to $11.00 and gave the stock an “overweight” rating in a research note on Monday, March 3rd. JPMorgan Chase & Co. upgraded shares of Amneal Pharmaceuticals from a “neutral” rating to an “overweight” rating and lifted their price objective for the stock from $9.00 to $12.00 in a research note on Monday, February 24th. Six investment analysts have rated the stock with a buy rating, According to MarketBeat, the company currently has a consensus rating of “Buy” and a consensus price target of $10.80.

Amneal Pharmaceuticals Price Performance

NASDAQ:AMRX opened at $7.25 on Wednesday. The company’s fifty day moving average price is $8.08 and its 200-day moving average price is $8.22. Amneal Pharmaceuticals, Inc. has a 1-year low of $5.36 and a 1-year high of $9.48. The firm has a market capitalization of $2.25 billion, a P/E ratio of -10.66 and a beta of 1.06.

Amneal Pharmaceuticals (NASDAQ:AMRX) last released its quarterly earnings data on Friday, February 28th. The company reported $0.12 EPS for the quarter, missing the consensus estimate of $0.15 by ($0.03). The company had revenue of $730.52 million during the quarter, compared to analysts’ expectations of $708.21 million. Amneal Pharmaceuticals had a negative return on equity of 346.26% and a negative net margin of 6.88%. During the same quarter in the prior year, the company posted $0.14 EPS. Equities analysts anticipate that Amneal Pharmaceuticals, Inc. will post 0.53 EPS for the current fiscal year.

Insider Buying and Selling at Amneal Pharmaceuticals

In other news, major shareholder Tushar Bhikhubhai Patel sold 5,000,000 shares of the business’s stock in a transaction that occurred on Friday, March 14th. The stock was sold at an average price of $8.35, for a total value of $41,750,000.00. Following the completion of the sale, the insider now directly owns 48,578,209 shares in the company, valued at $405,628,045.15. The trade was a 9.33 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, Director Gautam Patel sold 80,000 shares of the company’s stock in a transaction that occurred on Monday, March 3rd. The stock was sold at an average price of $8.90, for a total value of $712,000.00. Following the transaction, the director now directly owns 1,808,886 shares of the company’s stock, valued at approximately $16,099,085.40. The trade was a 4.24 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders sold 5,160,000 shares of company stock valued at $43,113,200. Corporate insiders own 17.45% of the company’s stock.

Amneal Pharmaceuticals Profile

Amneal Pharmaceuticals, Inc, together with its subsidiaries, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment offers immediate and extended release oral solid, powder, liquid, sterile injectable, nasal spray, inhalation and respiratory, biosimilar, ophthalmic, film, transdermal patch, and topical products.